| Literature DB >> 19582593 |
Victor N Uebele1, Cindy E Nuss, Steven V Fox, Susan L Garson, Razvan Cristescu, Scott M Doran, Richard L Kraus, Vincent P Santarelli, Yuxing Li, James C Barrow, Zhi-Qiang Yang, Kelly-Ann S Schlegel, Kenneth E Rittle, Thomas S Reger, Rodney A Bednar, Wei Lemaire, Faith A Mullen, Jeanine E Ballard, Cuyue Tang, Ge Dai, Owen B McManus, Kenneth S Koblan, John J Renger.
Abstract
Low-voltage-activated (T-type) calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. To better understand the biological role and therapeutic potential of the target, a number of structurally diverse antagonists have been identified. Multiple drug interaction sites have been identified for L-type calcium channels, suggesting a similar possibility exists for the structurally related T-type channels. Here, we radiolabel a novel amide T-type calcium channel antagonist (TTA-A1) and show that several known antagonists, including mibefradil, flunarizine, and pimozide, displace binding in a concentration-dependent manner. Further, we identify a novel quinazolinone T-type antagonist (TTA-Q4) that enhanced amide radioligand binding, increased affinity in a saturable manner and slowed dissociation. Functional evaluation showed these compounds to be state-dependent antagonists which show a positive allosteric interaction. Consistent with slowing dissociation, the duration of efficacy was prolonged when compounds were co-administered to WAG/Rij rats, a genetic model of absence epilepsy. The development of a T-type calcium channel radioligand has been used to demonstrate structurally distinct TTAs interact at allosteric sites and to confirm the potential for synergistic inhibition of T-type calcium channels with structurally diverse antagonists.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19582593 DOI: 10.1007/s12013-009-9057-4
Source DB: PubMed Journal: Cell Biochem Biophys ISSN: 1085-9195 Impact factor: 2.194